Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034)

Phase 2

Completed

Conditions: Endometriosis-related Pain

Interventions: Drug: Placebo
Drug: Gefapixant
Drug: Naproxen

First Posted Date: 2018-08-31

Last Posted Date: 2024-11-04

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 187

Registration Number: NCT03654326

Locations: 🇺🇸
Synexus US Phoenix Southeast ( Site 0729), Chandler, Arizona, United States
🇺🇸
Lynn Institute of the Ozarks ( Site 0720), Little Rock, Arkansas, United States
🇺🇸
Thameside OBGYN Center ( Site 0747), Groton, Connecticut, United States

and more 75 locations

Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)

Phase 2

Completed

Conditions: Bacteremia
Soft Tissue Infections
Skin Diseases, Infectious

Interventions: Drug: Daptomycin for Injection

First Posted Date: 2018-08-23

Last Posted Date: 2022-05-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 18

Registration Number: NCT03643952

Locations: 🇯🇵
Nihon University Itabashi Hospital ( Site 0029), Tokyo, Japan
🇯🇵
Saitama City Hospital ( Site 0008), Saitama, Japan
🇯🇵
Chiba Children's Hospital ( Site 0024), Chiba, Japan

and more 13 locations

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Phase 3

Completed

Conditions: Cervical Cancer

Interventions: Biological: Pembrolizumab
Drug: Paclitaxel
Drug: Cisplatin
Drug: Carboplatin
Drug: Placebo to pembrolizumab
Biological: Bevacizumab

First Posted Date: 2018-08-17

Last Posted Date: 2025-05-11

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 617

Registration Number: NCT03635567

Locations: 🇦🇺
Monash Health-Monash Medical Centre ( Site 1519), Clayton, Australia
🇺🇸
Seattle Cancer Care Alliance ( Site 1777), Seattle, Washington, United States
🇯🇵
Shizuoka Cancer Center Hospital and Research Institute ( Site 1703), Sunto-gun, Shizuoka, Japan

and more 146 locations

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pembrolizumab 200 mg
Drug: Paclitaxel 45 mg/m^2
Drug: Cisplatin 75 mg/m^2
Drug: Carboplatin AUC6
Drug: Pemetrexed 500 mg/m^2
Radiation: Thoracic Radiation Therapy (TRT)
Drug: Paclitaxel 200 mg/m^2
Drug: Carboplatin AUC2

First Posted Date: 2018-08-15

Last Posted Date: 2025-03-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 216

Registration Number: NCT03631784

Locations: 🇺🇸
Fox Chase Cancer Center ( Site 1433), Philadelphia, Pennsylvania, United States
🇺🇸
Parkview Cancer Institute ( Site 1415), Fort Wayne, Indiana, United States
🇺🇸
UMass Memorial Medical Center ( Site 1417), Worcester, Massachusetts, United States

and more 53 locations

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

Phase 2

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: Vicriviroc
Biological: Pembrolizumab

First Posted Date: 2018-08-15

Last Posted Date: 2024-11-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 41

Registration Number: NCT03631407

Locations: 🇺🇸
California Cancer Associates for Research & Excellence ( Site 0100), Encinitas, California, United States
🇺🇸
Baylor Scott & White Medical Center - Temple ( Site 0104), Temple, Texas, United States
🇨🇦
Cross Cancer Institute ( Site 0201), Edmonton, Alberta, Canada

and more 5 locations

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

Phase 3

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: Prevnar 13™
Biological: RotaTeq™
Biological: V114
Biological: Pentacel™
Biological: RECOMBIVAX HB™
Biological: HIBERIX™
Biological: M-M-R™ II
Biological: VARIVAX™

First Posted Date: 2018-08-08

Last Posted Date: 2023-01-17

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 900

Registration Number: NCT03620162

Locations: 🇺🇸
Coastal Pediatric Research ( Site 0006), Charleston, South Carolina, United States
🇺🇸
Davita Medical Group ( Site 0012), Colorado Springs, Colorado, United States
🇺🇸
Parkside Pediatric ( Site 0007), Greenville, South Carolina, United States

and more 31 locations

A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)

Phase 1

Completed

Conditions: Human Immunodeficiency Virus
AIDS Virus

Interventions: Drug: MK-8527

First Posted Date: 2018-08-03

Last Posted Date: 2020-09-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 17

Registration Number: NCT03615183

Locations: 🇷🇴
Matei Bals Infectious Diseases Institute ( Site 0001), Bucharest, Romania

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Phase 3

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: V114
Biological: QIV
Biological: Matching Placebo for V114

First Posted Date: 2018-08-03

Last Posted Date: 2024-05-22

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1200

Registration Number: NCT03615482

Locations: 🇺🇸
Center for Clinical Trials, LLC ( Site 0025), Paramount, California, United States
🇺🇸
Bayview Research Group, LLC ( Site 0010), Valley Village, California, United States
🇺🇸
Community Clinical Research Network (Marlboro, MA) ( Site 0030), Marlborough, Massachusetts, United States

and more 42 locations

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Phase 3

Active, not recruiting

Conditions: Gastric Neoplasms
Gastroesophageal Junction Adenocarcinoma

Interventions: Biological: Pembrolizumab
Biological: Placebo
Drug: Cisplatin
Drug: 5-FU
Drug: S-1
Drug: Oxaliplatin
Drug: Capecitabine
Biological: Trastuzumab

First Posted Date: 2018-08-03

Last Posted Date: 2025-03-17

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 738

Registration Number: NCT03615326

Locations: 🇪🇸
Hospital Universitario Central de Asturias ( Site 1402), Oviedo, Asturias, Spain
🇺🇸
Cancer Treatment Centers of America-Eastern Regional Medical Center ( Site 0025), Philadelphia, Pennsylvania, United States
🇺🇸
University of Rochester ( Site 0041), Rochester, New York, United States

and more 189 locations

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

Phase 1

Active, not recruiting

Conditions: Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Hodgkin Disease

Interventions: Biological: pembrolizumab
Biological: Favezelimab

First Posted Date: 2018-07-26

Last Posted Date: 2025-04-03

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 174

Registration Number: NCT03598608

Locations: 🇺🇸
Banner MD Anderson Cancer Center ( Site 0020), Gilbert, Arizona, United States
🇺🇸
City of Hope ( Site 0001), Duarte, California, United States
🇺🇸
Ronald Reagan UCLA Medical Center (Radiological Sciences) ( Site 0007), Los Angeles, California, United States

and more 22 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy